Trial Profile
Icatibant Outcome Survey (IOS) Registry
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Complement C1 inhibitor protein (Primary) ; Icatibant (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; Therapeutic Use
- Acronyms IOS
- Sponsors Shire; Takeda
- 21 Jul 2022 Planned End Date changed from 24 May 2023 to 31 Jan 2027.
- 21 Jul 2022 Planned primary completion date changed from 24 May 2023 to 31 Jan 2027.
- 20 May 2020 Status changed from active, no longer recruiting to recruiting.